209 related articles for article (PubMed ID: 15644571)
1. Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes.
Hirata K; Kubo K
Endocr J; 2004 Dec; 51(6):537-44. PubMed ID: 15644571
[TBL] [Abstract][Full Text] [Related]
2. Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy.
Ghanem AA; Elewa A; Arafa LF
Eur J Ophthalmol; 2011; 21(1):48-54. PubMed ID: 20544678
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.
Miura J; Yamagishi Si; Uchigata Y; Takeuchi M; Yamamoto H; Makita Z; Iwamoto Y
J Diabetes Complications; 2003; 17(1):16-21. PubMed ID: 12505751
[TBL] [Abstract][Full Text] [Related]
4. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
Kerkeni M; Saïdi A; Bouzidi H; Letaief A; Ben Yahia S; Hammami M
Diab Vasc Dis Res; 2013 May; 10(3):239-45. PubMed ID: 23091285
[TBL] [Abstract][Full Text] [Related]
5. Increased serum levels of pentosidine, but not carboxymethyl lysine, in type 2 diabetes without obvious diabetic nephropathy.
Daimon M; Ono Y; Saito T; Yamaguchi H; Hirata A; Ohnuma H; Igarashi M; Eguchi H; Manaka H; Kato T
Diabetes Care; 1999 May; 22(5):877-8. PubMed ID: 10332715
[No Abstract] [Full Text] [Related]
6. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product.
Sugiyama S; Miyata T; Ueda Y; Tanaka H; Maeda K; Kawashima S; Van Ypersele de Strihou C; Kurokawa K
J Am Soc Nephrol; 1998 Sep; 9(9):1681-8. PubMed ID: 9727377
[TBL] [Abstract][Full Text] [Related]
7. Correlation between plasma pentosidine concentrations and retinal hemodynamics in patients with type 2 diabetes.
Sato E; Nagaoka T; Yokota H; Takahashi A; Yoshida A
Am J Ophthalmol; 2012 May; 153(5):903-909.e1. PubMed ID: 22265156
[TBL] [Abstract][Full Text] [Related]
8. Pentosidine - a new biochemical marker in diabetic retinopathy.
Salman AG; Mansour DE; Swelem AH; Al-Zawahary WM; Radwan AA
Ophthalmic Res; 2009; 42(2):96-8. PubMed ID: 19546600
[TBL] [Abstract][Full Text] [Related]
9. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus.
McCance DR; Dyer DG; Dunn JA; Bailie KE; Thorpe SR; Baynes JW; Lyons TJ
J Clin Invest; 1993 Jun; 91(6):2470-8. PubMed ID: 8514859
[TBL] [Abstract][Full Text] [Related]
10. Skin collagen pentosidine and fluorescence in diabetes were predictors of retinopathy progression and creatininemia increase already 6years after punch-biopsy.
Sternberg M; M'bemba J; Urios P; Borsos AM; Selam JL; Peyroux J; Slama G
Clin Biochem; 2016 Feb; 49(3):225-31. PubMed ID: 26506116
[TBL] [Abstract][Full Text] [Related]
11. Development and Application of Mass Spectroscopy Assays for Nε-(1-Carboxymethyl)-L-Lysine and Pentosidine in Renal Failure and Diabetes.
O'Grady KL; Khosla S; Farr JN; Bondar OP; Atkinson EJ; Achenbach SJ; Eckhardt BA; Thicke BS; Tweed AJ; Volkman TL; Drake MT; Hines JM; Singh RJ
J Appl Lab Med; 2020 May; 5(3):558-568. PubMed ID: 32445362
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
Busch M; Franke S; Wolf G; Rohde RD; Stein G;
Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy.
Kerkeni M; Saïdi A; Bouzidi H; Ben Yahya S; Hammami M
Microvasc Res; 2012 Nov; 84(3):378-83. PubMed ID: 22835520
[TBL] [Abstract][Full Text] [Related]
14. The effects of n-3 long-chain polyunsaturated fatty acid supplementation on AGEs and sRAGE in type 2 diabetes mellitus.
Kurt A; Andican G; Siva ZO; Andican A; Burcak G
J Physiol Biochem; 2016 Dec; 72(4):679-687. PubMed ID: 27448155
[TBL] [Abstract][Full Text] [Related]
15. Pentosidine plasma levels and relation with metabolic control in diabetic patients.
Lapolla A; Reitano R; Baccarin L; Sartore G; Plebani M; Fedele D
Horm Metab Res; 2005 Apr; 37(4):252-6. PubMed ID: 15952087
[TBL] [Abstract][Full Text] [Related]
16. Dissociation between urinary pyrraline and pentosidine concentrations in diabetic patients with advanced nephropathy.
Aso Y; Takanashi K; Sekine K; Yoshida N; Takebayashi K; Yoshihara K; Inukai T
J Lab Clin Med; 2004 Aug; 144(2):92-9. PubMed ID: 15322503
[TBL] [Abstract][Full Text] [Related]
17. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients.
Wautier MP; Massin P; Guillausseau PJ; Huijberts M; Levy B; Boulanger E; Laloi-Michelin M; Wautier JL
Diabetes Metab; 2003 Feb; 29(1):44-52. PubMed ID: 12629447
[TBL] [Abstract][Full Text] [Related]
18. Soluble receptor for advanced glycation end-product (sRAGE)/pentosidine ratio: a potential risk factor determinant for type 2 diabetic retinopathy.
Ng ZX; Chua KH; Iqbal T; Kuppusamy UR
Int J Mol Sci; 2013 Apr; 14(4):7480-91. PubMed ID: 23552832
[TBL] [Abstract][Full Text] [Related]
19. Improvement in quality of diabetes control and concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus studied over a period of 10 years (JEVIN).
Schiel R; Franke S; Appel T; Voigt U; Ross IS; Kientsch-Engel R; Stein G; Müller UA
J Diabetes Complications; 2003; 17(2):90-7. PubMed ID: 12614975
[TBL] [Abstract][Full Text] [Related]
20. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
